Menopause Support Protocol

Overview

Menopause — defined as 12 months past the final menstrual period — is a normal physiologic transition, but perimenopause and postmenopause carry real health implications: accelerated bone loss, cardiovascular risk shift, vasomotor symptoms, sleep disruption, genitourinary changes, cognitive changes, and body composition shifts.

Modern menopause care has been through a long pendulum swing. Post-WHI concerns about HRT have largely been revised as subsequent analyses clarified that for healthy women within 10 years of menopause and under 60, hormone therapy's benefits typically outweigh risks. This protocol takes an evidence-based framework and adds adjunctive tools where appropriate. It is not a DIY replacement for gynecologic or menopause-specialist care.

Compounds Involved

Estradiol + Progesterone

Transdermal estradiol avoids the first-pass hepatic effects of oral estrogen and is associated with lower VTE risk than oral. Oral micronized progesterone is used in women with an intact uterus for endometrial protection and has useful sleep benefits at bedtime dosing.

Low-Dose Testosterone

Physiologic-dose testosterone for women (roughly one-tenth of male dosing) can meaningfully help libido, energy, and mood in the appropriate patient. International guidelines specifically support its use for postmenopausal HSDD.

GH Secretagogues

Low-dose Ipamorelin/CJC-1295 pre-bed can support sleep architecture and body composition during the menopause transition when GH secretion has already begun to decline.

Protocol Structure

Phase 1 — Evaluation (Weeks 1–4)

• Workup with a menopause-literate clinician — symptom inventory, FSH/estradiol if unclear, thyroid panel, lipid panel, HbA1c, vitamin D, ferritin
• Bone health — baseline DEXA for women around 50–55 or earlier if risk factors; vitamin D optimization
• Breast and pelvic screening — current mammography and cervical screening per guidelines
• Cardiovascular — baseline BP, lipid panel, consider CAC score

Phase 2 — Hormone Therapy Initiation (Weeks 4–12)

Under clinician supervision:

• Transdermal estradiol patch 0.05 mg/day, applied twice weekly, titrate to symptom relief
• Oral micronized progesterone 100 mg at bedtime (continuous), or cyclic 200 mg × 12 days/month for women near menopause who want a predictable bleed
• Consider low-dose testosterone if libido, energy, or mood remain problematic after estrogen is optimized
• Lifestyle: adequate protein (1.2–1.6 g/kg), resistance training 2–3x/week, weight-bearing cardio

Phase 3 — Adjunctive Peptide Layer (Month 3 onward, optional)

• Ipamorelin 200 mcg + CJC-1295 (no-DAC) 100 mcg subcutaneous pre-bed, 5 nights/week
• BPC-157 250 mcg/day subcutaneous for joint and connective tissue complaints that often emerge in perimenopause
• See Bone Density Protocol if DEXA shows significant osteopenia

Phase 4 — Long-Term Maintenance

• Annual clinician review of hormone therapy benefit/risk balance
• DEXA every 2 years, or per clinical judgment
• Cardiovascular risk-factor tracking
• Peptide cycling: 12 weeks on, 4 weeks off for GH secretagogues
• Maintain resistance training indefinitely — it is the single most durable intervention against sarcopenia and bone loss in this population

Important Considerations

• Hormone therapy contraindications include history of estrogen-sensitive cancer, recent VTE, active liver disease, unexplained vaginal bleeding, and a handful of less common conditions; clinical evaluation is essential.
• Transdermal estrogen generally has a better VTE risk profile than oral.
• Women with an intact uterus on estrogen must have progestin for endometrial protection; unopposed estrogen is not safe.
• Testosterone dosing in women is an order of magnitude lower than in men; over-dosing produces acne, hirsutism, voice changes, and other androgenic effects that may not fully reverse.
• GH secretagogues can modestly reduce insulin sensitivity; monitor fasting glucose in women with insulin resistance.
• Non-hormonal options (SSRIs, gabapentin, oxybutynin, fezolinetant) are available for women who cannot or choose not to use hormone therapy.
• Bone loss is fastest in the first 5–7 years postmenopause; early intervention matters most.
• Sleep disruption in menopause is often multifactorial (vasomotor symptoms, reduced progesterone, sleep apnea emerging) — evaluate rather than assume.

Disclaimer

This content is for educational and informational purposes only and is not medical advice. Menopause management involves significant individualized decisions about benefit/risk balance, particularly around hormone therapy. Consult a qualified gynecologist or menopause specialist for personalized care. The peptides discussed as adjunctive are not FDA-approved for menopause indications and are sold as research chemicals in most jurisdictions. Pepperpedia does not endorse the acquisition or use of unapproved substances or the use of prescription hormones outside of physician-directed care.